The MPP invites Expression of Interest from potential sublicensees for licences to manufacture and sell bictegravir, tenovofir alafenamide, tenofovir disoproxil fumarate, dolutegravir, lopinavir, ritonavir and daclatasvir.
EXPANSION OF THE PATENT AND LICENSING DATABASE, MEDSPAL, TO INCLUDE ESSENTIAL MEDICINES FOR CANCER
MedsPaL, a comprehensive resource for information on the intellectual property status of priority medicines in developing countries, has been expanded to patented treatments on the World Health Organization’s Model List of Essential Medicines.
The MPP’s patents and licences database, MedsPaL is an information resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
Former President of the World Hepatitis Alliance brings two decades of experience in public health, patient advocacy and coalition-building to the organisation
Geneva, 19 April 2018 — The Medicines Patent Pool (MPP) Governance Board today announced the appointment of Charles Gore, founder and former President of the World Hepatitis Alliance, as new MPP Executive Director. Mr. Gore succeeds Greg Perry, Executive Director of the organisation from 2013-2017.
Mr. Gore brings to the MPP two decades of work as an advocate for hepatitis C patients and better treatment alternatives. He established the World Hepatitis Alliance in 2007 to raise awareness of viral hepatitis and, under his leadership, it worked with key countries on three World Health Assembly resolutions, culminating in the global agreement to eliminate viral hepatitis by 2030. The World Hepatitis Alliance has become the largest membership-based hepatitis patient group globally, with 250 member patient organisations from more than 90 nations. Mr....
Geneva, 15 February 2018 - The Medicines Patent Pool (MPP) signed a collaborative agreement with the African Regional Intellectual Property Organization (ARIPO), an intergovernmental organisation that facilitates cooperation among 19 African states in patent and intellectual property issues. ARIPO will support the continued improvement of, and data collection for, MedsPaL, the MPP’s signature resource for patent and licensing information in low- and middle-income countries.
The MPP launched MedsPaL in 2016 to provide information on the patent and licensing status of HIV, hepatitis C and tuberculosis medicines. It expanded the database in late 2017 to include other patented medicines on the World Health Organization’s Essential Medicines List. Today, MedsPaL covers 6,800 national patent applications in more than 110 countries for more than 70 priority treatments.
ARIPO is the second regional patent organisation to sign a collaborative agreement with the MPP. The foundation also has a memorandum of unde...
The Medicines Patent Pool (MPP) is currently inviting interested product developers to indicate an interest in a sublicence for investigational hepatitis C (HCV) treatment ravidasvir. Pharco Pharmaceuticals granted the MPP a non-exclusive, royalty-bearing licence which allows sublicensees to develop, make, have made, use, file for regulatory approval, sell, import and export ravidasvir. The full text of the agreement can be found here.
Per the licence’s terms and conditions, the MPP seeks to grant sublicences to any entity that can demonstrate a willingness and capacity to further develop and commercialise the product and make the product widely available in the Territory. The MPP will also require any sublicensee to agree upon reasonable diligence requirements and development milestones.
Interested parties should also submit as much detail as possible to help MPP understand whether, and to what extent, a granted sublicence will help improve sustainable access to improved regimens to treat HCV. Applicat...
“Successful cooperation of the Ministry of Health of Belarus with the Medicines Patent Pool is crucial in light of our current work to achieve the “90-90-90” goals and put an end to the epidemic in the country which is only possible when access to affordabl...”